MX2016013190A - Formulacion homogenea que comprende acido graso poliinsaturado omega-3 y resveratrol para administracion oral. - Google Patents

Formulacion homogenea que comprende acido graso poliinsaturado omega-3 y resveratrol para administracion oral.

Info

Publication number
MX2016013190A
MX2016013190A MX2016013190A MX2016013190A MX2016013190A MX 2016013190 A MX2016013190 A MX 2016013190A MX 2016013190 A MX2016013190 A MX 2016013190A MX 2016013190 A MX2016013190 A MX 2016013190A MX 2016013190 A MX2016013190 A MX 2016013190A
Authority
MX
Mexico
Prior art keywords
resveratrol
omega
oral administration
fatty acid
homogeneous formulation
Prior art date
Application number
MX2016013190A
Other languages
English (en)
Other versions
MX361765B (es
Inventor
Giannini Giuseppe
SANTANIELLO Mosé
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of MX2016013190A publication Critical patent/MX2016013190A/es
Publication of MX361765B publication Critical patent/MX361765B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

La presente invención se refiere a formulaciones homogéneas que comprenden ácidos grasos poliinsaturados omega-3 (n-3 PUFA) y resveratrol para administración oral, en la cuales el resveratrol se solubiliza en un sistema de solventes que comprenden ácidos grasos poliinsaturados omega-3 (n-3 PUFA), o sus esteres de alquilo, y un emulsionador iónico. La composición de acuerdo a la presente invención se puede formular, como complemento alimenticio nutricional o medicamento en la prevención o tratamiento de enfermedades cardiovasculares debidas a trastornos en el metabolismo de los lípidos y a agregación incrementada de plaquetas, así como a daños debidos a radicales libres y/o enfermedades virales.
MX2016013190A 2014-06-04 2015-03-26 Formulacion homogenea que comprende acido graso poliinsaturado omega-3 y resveratrol para administracion oral. MX361765B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14001941.5A EP2952209B1 (en) 2014-06-04 2014-06-04 Homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 PUFA) and resveratrol for oral administration
PCT/EP2015/056524 WO2015185238A1 (en) 2014-06-04 2015-03-26 Homogeneous formulation comprising omega-3 polyunsatured fatty acid and resveratrol for oral administration

Publications (2)

Publication Number Publication Date
MX2016013190A true MX2016013190A (es) 2017-01-09
MX361765B MX361765B (es) 2018-12-17

Family

ID=50884651

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013190A MX361765B (es) 2014-06-04 2015-03-26 Formulacion homogenea que comprende acido graso poliinsaturado omega-3 y resveratrol para administracion oral.

Country Status (13)

Country Link
US (1) US10300035B2 (es)
EP (1) EP2952209B1 (es)
JP (1) JP6552526B2 (es)
CN (1) CN106456783B (es)
AU (1) AU2015271277A1 (es)
CA (1) CA2943000A1 (es)
EA (1) EA032717B1 (es)
ES (1) ES2666836T3 (es)
MX (1) MX361765B (es)
PL (1) PL2952209T3 (es)
PT (1) PT2952209T (es)
UA (1) UA118289C2 (es)
WO (1) WO2015185238A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114569726B (zh) * 2022-05-06 2022-10-28 太阳雨林(北京)生物医药有限公司 预防、阻止或治疗微生物感染的复合物及制备方法和用途
WO2023213310A1 (zh) * 2022-05-06 2023-11-09 太阳雨林(北京)生物医药有限公司 调节细胞膜跨膜运输和流动性的碳链物质、制备及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
ITRM20020562A1 (it) 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
EP1863570B1 (en) * 2005-03-11 2011-02-23 Recon Oil Industries Private Limited A synergistically heat stable oil media having eicosa pentaenoic acid (epa) and docosa hexaenoic acid (dha)
KR101100078B1 (ko) * 2008-03-27 2011-12-29 홉킨스바이오연구센터(주) 관절염 치료를 위한 약제학적 조성물
JP2013515719A (ja) 2009-12-23 2013-05-09 デフィアンテ・ファルマセウティカ・ソシエダデ・アノニマ 循環器疾患の処置に有用な組み合わせ組成物
US20110244031A1 (en) 2010-03-31 2011-10-06 Lifecycle Pharma A/S Porous tablets as carriers for liquid formulations
IT1400695B1 (it) 2010-06-21 2013-06-28 Labomar S R L Composizioni farmaceutiche e/o nutraceutiche contenenti principi attivi insolubili in acqua e procedimento per ottenerle.
WO2011162802A1 (en) * 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
CN102228089B (zh) * 2011-06-22 2013-02-20 刘升胜 一种天然复合食用植物健脑营养饮料
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
WO2014095628A1 (en) * 2012-12-17 2014-06-26 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa)

Also Published As

Publication number Publication date
EA032717B1 (ru) 2019-07-31
JP2017516820A (ja) 2017-06-22
US20170119720A1 (en) 2017-05-04
UA118289C2 (uk) 2018-12-26
CA2943000A1 (en) 2015-12-10
JP6552526B2 (ja) 2019-07-31
US10300035B2 (en) 2019-05-28
EA201692398A1 (ru) 2017-04-28
CN106456783B (zh) 2020-06-12
WO2015185238A1 (en) 2015-12-10
ES2666836T3 (es) 2018-05-08
MX361765B (es) 2018-12-17
AU2015271277A1 (en) 2016-11-10
PT2952209T (pt) 2018-05-09
CN106456783A (zh) 2017-02-22
PL2952209T3 (pl) 2018-07-31
EP2952209A1 (en) 2015-12-09
EP2952209B1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
PH12015501751A1 (en) Nutritional compositions containing an enriched lipid fraction and uses thereof
MY165048A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
MX2015008199A (es) Formulaciones de acido eicosapentaenoico (epa).
PH12018500090A1 (en) Nutritional compositions and methods for promoting cognitive development
PH12017500074A1 (en) Nutritional compositions containing oil blends and uses thereof
MY189576A (en) Omega-3 fatty acid ester compositions
PH12018500035A1 (en) Nutritional compositions and methods for promoting cognitive development
MX2014000770A (es) Composiciones de acidos grasos.
NZ630210A (en) Nutritional compositions including rrr -alpha tocopherol and polyunsaturated fatty acids
WO2016040570A3 (en) Dietary emulsion formulations and methods for using the same
GEP201606568B (en) Compositions for the treatment of neurologic disorders
HRP20201221T1 (hr) Sastavi omega 3 masnih kiselina za liječenje bolesti koje uključuju štete nastale u živčanom sustavu
MY181997A (en) Preparation and composition of medium chain triglycerides containing substantial amount of lauric acid
MX2018000847A (es) Analogos metabolicamente robustos de cyp-eicosanoides para el tratamiento de enfermedades cardiacas.
MX2016013190A (es) Formulacion homogenea que comprende acido graso poliinsaturado omega-3 y resveratrol para administracion oral.
MX2015007082A (es) Métodos de administración de composiciones que comprenden ácido docosapentanoico.
IN2014DN05811A (es)
TW201613477A (en) Oil and fat composition for assisting ingestion of foods for persons having swallowing and/or chewing difficulties, and foods for persons having swallowing and/or chewing difficulties
MX2017004839A (es) Composiciones de acidos grasos monoinsaturados y uso para tratar la ateroesclerosis.
GB201209344D0 (en) Omega-6 enriched pufa phospholipids
MX369782B (es) Formulaciones solidas que contienen omega-3 y resveratrol.
MX2017016991A (es) Formulación para la administración oral de extracto de arándano azul como auxiliar en la conservación de la salud de la película lagrimal en seres humanos.
WO2015095570A3 (en) Nutritional composition comprising hydrolyzed protein
MX2015005235A (es) Metodo para reducir trigliceridos.
GB201607617D0 (en) Use of EPA and DHA Omega3 Dietary supplementation and Omega6 polyunsaturated fatty acid dietary restriction to cure 2 type diabetes

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ALFASIGMA S.P.A.

FG Grant or registration